First‐line atezolizumab monotherapy in patients with advanced BRAF V600 wild‐type melanoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

First‐line atezolizumab monotherapy in patients with advanced BRAF V600 wild‐type melanoma

Published:2021-02-15 Issue:5 Volume:34 Page:973-977
ISSN:1755-1471
Container-title:Pigment Cell & Melanoma Research
language:en
Short-container-title:Pigment Cell Melanoma Res

Author:

Azevedo Sergio Jobim¹^ORCID,Melo Andreia Cristina²,Roberts Louise³,Caro Ivor³,Xue Cloris⁴,Wainstein Alberto⁵

Affiliation:

1. Hospital de Clínicas de Porto Alegre Unidade de Pesquisa Clinica em Oncologia Porto Alegre Brazil

2. Instituto Nacional de Câncer Rio de Janeiro Brazil

3. Genentech/Roche South San Francisco CA USA

4. Hoffmann‐La Roche Limited Mississauga ON Canada

5. Cenantron Centro Avançado de Tratamento Oncológico, Ltda. Belo Horizonte Brazil

Publisher

Wiley

Subject

Dermatology,General Biochemistry, Genetics and Molecular Biology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/pcmr.12960

Reference8 articles.

1. Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

2. Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study

3. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

4. Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in immunotherapy and its combination therapies for advanced melanoma: a review;Frontiers in Oncology;2024-07-16

2. Nanoparticle‐Mediated Tumor Microenvironment Remodeling Favors the Communication with the Immune Cells for Tumor Killing;Advanced Therapeutics;2024-03-03

3. Evaluating the Mechanism of Cell Death in Melanoma Induced by the Cannabis Extract PHEC-66;Cells;2024-01-31

4. Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis;Cancers;2024-01-13

5. Immunotherapy Combined with Radiation in Malignant Melanoma without BRAF Mutations Brain Metastases—Favorable Response after Immunotherapy Continued beyond Progression;Journal of Personalized Medicine;2024-01-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3